Category News

Daiichi Sankyo Highlights Inequalities and Unmet Needs in Cardiovascular Care as Part of Its Commitment to Patients

Daiichi Sankyo Europe (Daiichi Sankyo) has reaffirmed its commitment to addressing unmet needs and barriers in cardiovascular (CV) care by highlighting disparities in treatment and outcomes among different patient groups. This announcement follows the presentation of new data from sub-analyses…

Read MoreDaiichi Sankyo Highlights Inequalities and Unmet Needs in Cardiovascular Care as Part of Its Commitment to Patients

Anthos Therapeutics Highlights Low Bleeding Risk with Abelacimab in AZALEA-TIMI 71 AF Study

Anthos Therapeutics, Inc., a cutting-edge clinical-stage biopharmaceutical company focused on developing innovative treatments for cardiovascular and metabolic diseases, announced significant findings from the AZALEA-TIMI 71 study at the European Society for Cardiology (ESC) Congress. The study revealed that approximately 1%…

Read MoreAnthos Therapeutics Highlights Low Bleeding Risk with Abelacimab in AZALEA-TIMI 71 AF Study

European Commission Approves Astellas’ PADCEV with KEYTRUDA for Advanced Urothelial Cancer

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) has announced that the European Commission has granted Marketing Authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the first-line treatment…

Read MoreEuropean Commission Approves Astellas’ PADCEV with KEYTRUDA for Advanced Urothelial Cancer

Roche’s PiaSky Receives EU Approval as the First Monthly Subcutaneous Treatment for PNH Patients

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission has approved PiaSky® (crovalimab), a novel monoclonal antibody designed to inhibit the complement protein C5, for the treatment of adults and adolescents (12 years and older, weighing at…

Read MoreRoche’s PiaSky Receives EU Approval as the First Monthly Subcutaneous Treatment for PNH Patients

MedImpact Broadens Access to Two Humira Biosimilars for New Patients

MedImpact Healthcare Systems, Inc., the largest independent provider of health solutions, technology, and pharmacy benefit services in the U.S., announced today the expansion of access to Humira biosimilars—Simlandi and adalimumab-adaz—for new patients needing treatment for inflammatory conditions like Crohn’s disease…

Read MoreMedImpact Broadens Access to Two Humira Biosimilars for New Patients